share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144：擬議出售證券
美股SEC公告 ·  07/24 04:22
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, Inc. Director Borgeson Blake is set to sell 11,447 Class A shares of the company, with an aggregate market value of $97,040.46, on 07/23/2024. These shares were originally acquired on 09/01/2016 as founder's shares and were part of Blake's compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 77,289 shares were sold for gross proceeds of $688,144.26.
Recursion Pharmaceuticals, Inc. Director Borgeson Blake is set to sell 11,447 Class A shares of the company, with an aggregate market value of $97,040.46, on 07/23/2024. These shares were originally acquired on 09/01/2016 as founder's shares and were part of Blake's compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 77,289 shares were sold for gross proceeds of $688,144.26.
Recursion Pharmaceuticals, Inc.董事Borgeson Blake計劃出售11,447股A類公司股票，市值總計$97,040.46，時間爲2024年07月23日。這些股票最初是在2016年09月01日作爲創始人股份獲得的，並且是Blake從發行人處獲得的報酬的一部分。這次計劃的銷售是在過去三個月的一系列交易之後進行的，共售出77,289股，毛收入爲$688,144.26。
Recursion Pharmaceuticals, Inc.董事Borgeson Blake計劃出售11,447股A類公司股票，市值總計$97,040.46，時間爲2024年07月23日。這些股票最初是在2016年09月01日作爲創始人股份獲得的，並且是Blake從發行人處獲得的報酬的一部分。這次計劃的銷售是在過去三個月的一系列交易之後進行的，共售出77,289股，毛收入爲$688,144.26。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。